Erik de Clercq
Direktor/Vorstandsmitglied bei FermaVir Pharmaceuticals LLC
Profil
Erik De Clercq has been a Director of FermaVir Pharmaceuticals, Inc. since August 16, 2005 and FermaVir Research, Inc. since March, 2005.
He has been working with Rega Institute in Leuven since 1977.
Dr. De Clercq is a Professor of the Medical School at Leuven University, Leuven, Belgium.
He is Chairman and a Director of the Rega Institute and the Rega Foundation and Chairman of the Department of Microbiology and Immunology at Leuven University.
Aktive Positionen von Erik de Clercq
Unternehmen | Position | Beginn |
---|---|---|
FermaVir Pharmaceuticals LLC
FermaVir Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology FermaVir Pharmaceuticals, Inc. develops pharmaceutical products. The company manufactures compounds for the treatment of varicella zoster virus and chickenpox and human cytomegalovirus. It conducts preclinical trials on FV-100, a prodrug of a compound CF-1743, for the treatment of shingles. FermaVir Pharmaceuticals was founded in December, 2004 and is headquartered in New York City, NY. | Direktor/Vorstandsmitglied | 16.08.2005 |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Private Unternehmen | 1 |
---|---|
FermaVir Pharmaceuticals LLC
FermaVir Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology FermaVir Pharmaceuticals, Inc. develops pharmaceutical products. The company manufactures compounds for the treatment of varicella zoster virus and chickenpox and human cytomegalovirus. It conducts preclinical trials on FV-100, a prodrug of a compound CF-1743, for the treatment of shingles. FermaVir Pharmaceuticals was founded in December, 2004 and is headquartered in New York City, NY. | Health Technology |